华森制药
(002907)
| 流通市值：43.46亿 | | | 总市值：58.76亿 |
| 流通股本：3.09亿 | | | 总股本：4.18亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 614,223,361.57 | 417,852,265.17 | 228,392,771.39 | 691,542,793.48 |
| 营业收入 | 614,223,361.57 | 417,852,265.17 | 228,392,771.39 | 691,542,793.48 |
| 二、营业总成本 | 534,304,062.41 | 361,848,490.3 | 180,610,872.95 | 655,558,798.19 |
| 营业成本 | 259,861,828.77 | 175,944,194.61 | 89,843,761.05 | 311,348,443.65 |
| 税金及附加 | 7,833,077.47 | 6,051,458.26 | 2,054,123.11 | 11,008,221.34 |
| 销售费用 | 196,181,589.06 | 133,698,419.66 | 68,013,058.22 | 210,739,675.26 |
| 管理费用 | 41,032,795.9 | 27,768,062.4 | 12,759,134.86 | 53,139,702.38 |
| 研发费用 | 38,987,662.38 | 25,843,637.72 | 12,644,702.28 | 78,119,916.11 |
| 财务费用 | -9,592,891.17 | -7,457,282.35 | -4,703,906.57 | -8,797,160.55 |
| 其中:利息费用 | -344,416.8 | 4,338.7 | - | 945,351.05 |
| 其中:利息收入 | 9,333,877.67 | 7,513,021.29 | 4,732,980.35 | 9,810,172.49 |
| 加:公允价值变动收益 | 437,865.06 | 90,100.79 | - | 3,452,053.36 |
| 加:投资收益 | -3,438,914.87 | -2,836,418.72 | -371,713.79 | -8,121,359.49 |
| 资产处置收益 | - | - | - | 58,474.68 |
| 资产减值损失(新) | -1,068,293.84 | -397,153.79 | -68,066.4 | -1,097,450.45 |
| 信用减值损失(新) | -3,861,266.09 | -2,198,119.49 | -2,908,718.03 | 1,594,783.82 |
| 其他收益 | 17,066,173.96 | 6,976,770.02 | 3,611,997.92 | 13,952,536.22 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 89,054,863.38 | 57,638,953.68 | 48,045,398.14 | 45,823,033.43 |
| 加:营业外收入 | 202,728.95 | 75,142.94 | 39,446.94 | 148,645.15 |
| 减:营业外支出 | 584,723.52 | 513,852.35 | 18,612.28 | 3,174,905.81 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 88,672,868.81 | 57,200,244.27 | 48,066,232.8 | 42,796,772.77 |
| 减:所得税费用 | 14,096,033.18 | 9,985,348.15 | 7,714,980.73 | 10,097,622.55 |
| 六、净利润 | 74,576,835.63 | 47,214,896.12 | 40,351,252.07 | 32,699,150.22 |
| 持续经营净利润 | 74,576,835.63 | 47,214,896.12 | 40,351,252.07 | 32,699,150.22 |
| 归属于母公司股东的净利润 | 74,576,835.63 | 47,214,896.12 | 40,351,252.07 | 32,699,150.22 |
| (一)基本每股收益 | 0.18 | 0.11 | 0.1 | 0.08 |
| (二)稀释每股收益 | 0.18 | 0.11 | 0.1 | 0.08 |
| 八、其他综合收益 | -173,845.46 | 101,866.35 | 28,420.1 | 47,047.57 |
| 归属于母公司股东的其他综合收益 | -173,845.46 | 101,866.35 | 28,420.1 | 47,047.57 |
| 九、综合收益总额 | 74,402,990.17 | 47,316,762.47 | 40,379,672.17 | 32,746,197.79 |
| 归属于母公司股东的综合收益总额 | 74,402,990.17 | 47,316,762.47 | 40,379,672.17 | 32,746,197.79 |
| 公告日期 | 2024-10-29 | 2024-08-22 | 2024-04-29 | 2024-04-10 |
| 审计意见(境内) | | | | 标准无保留意见 |